secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2024-03-01T23:59:59+00:00
Accession:  0001790340-24-000022
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering reports $85.7M cash, net loss $53.5M in 2023; trial milestones ahead
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $85.7M as of Dec 31, 2023; cash runway into 2H 2025.
- Net loss Q4 2023 $15.1M ($0.52 per share); full year net loss $53.5M ($1.88 per share).
- FDA Fast Track designation for IMM-1-104 in pancreatic cancer received Feb 2024.
- Topline Phase 1 data for IMM-1-104 expected March 2024; first patient in Phase 2a expected March 2024.
- First patient dosing in Phase 1/2a trial of IMM-6-415 expected March 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000179034024000022/0001790340-24-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000179034024000022/imrx-20240301.htm
  HTML page:      https://secwatch.observer/filing/0001790340-24-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer